Taking aim at disease

February 16, 2024, 3:02PMNuclear NewsKristi Nelson Bumpus
ORNL radioisotope manufacturing coordinator Jillene Sennon-Greene places a shipment vial of actinium-225 inside the dose calibrator to confirm its activity is within customer specifications. (Photo: Carlos Jones/ORNL, DOE)

On August 2, 1946, 1 millicurie of the isotope carbon-14 left Oak Ridge National Laboratory, bound for the Barnard Free Skin and Cancer Hospital in St. Louis, Mo.

That tiny amount of the radioisotope was purchased by the hospital for use in cancer studies. And it heralded a new peacetime mission for ORNL, built just a few years earlier for the production of plutonium from uranium for the Manhattan Project.

To continue reading, log in or create a free account!

Related Articles

My story: Abraham Weitzberg, ANS member since 1962

November 25, 2025, 9:31AMANS NewsAbraham Weitzberg

My first exposure to nuclear engineering was in 1956–57 when I was a fourth-­year chemical engineering undergraduate at MIT. The previous summer, I worked at an oil refinery in New Jersey...

X-energy begins irradiation testing at INL

November 12, 2025, 3:01PMNuclear News

Advanced reactor and fuel developer X-energy has officially begun confirmatory irradiation testing at Idaho National Laboratory on its TRISO-X fuel. The testing, which is taking place over the...